3- benzenesulfonyl- 8- piperazin- 1- ylquinoline

06/01/2015 - "Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease."
02/01/2011 - "There is even an antagonist, SB-742457, that has completed phase II trials for the treatment of Alzheimer's disease. "
06/01/2015 - "Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT6) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD). "
05/01/2011 - "SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study."
08/01/2010 - "This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of the 5-HT6 receptor antagonist, SB-742457, in subjects with mild-to-moderate probable Alzheimer's disease (AD). "

01/01/2021 - "An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB)."
01/01/2021 - "A phase 2b clinical trial, HEADWAY-DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). "
01/01/2021 - "Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate AD dementia patients."
01/01/2021 - "A previous phase 2b study supported the use of the 5-HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. "

06/01/2011 - "SB-742457 is a potent 5-HT(6) antagonist and has shown efficacy in different animal models of cognitive impairment. "
01/01/2020 - "Among small molecules, most of them that are present in the last phases act as specific antagonists (Suvorexant, Idalopirdine, Intepirdine, Trazodone, Carvedilol, and Risperidone) or agonists (Dextromethorphan, Resveratrol, Brexpiprazole) and frequently ameliorate cognitive dysfunctions. "

06/09/2016 - "Compound SB-742457, used as comparator, reversed memory deficits in NOR task in similar doses, while in FST it was active in 10-30-fold higher dose (3 mg/kg). "
01/01/2016 - "Both compounds 14 and SB-742457 reversed phencyclidine-induced memory deficits and displayed distinct procognitive properties in cognitively unimpaired animals (3 mg/kg) in NOR tasks. "

01/20/2023 - "SB-742457 inhibited increased weight gain and alleviated hyperglycemia induced by APDs more strongly than did WAY-181187, but also intensified dyslipidemia. "